RDNT Quote, Financials, Valuation and Earnings

Quest Diagnostics has a net margin of 0.7% compared to RadNet's net margin of 9.08%. RadNet's return on equity of -0.45% beat Quest Diagnostics's return on equity of 12.68%.

RadNet has a consensus price target of $68.17, signalling upside risk potential of 23.91%. On the other hand Quest Diagnostics has an analysts' consensus of $169.77 which suggests that it could grow by 10.89%. Given that RadNet has higher upside potential than Quest Diagnostics, analysts believe RadNet is more attractive than Quest Diagnostics.

RadNet has a beta of 1.768, which suggesting that the stock is 76.83% more volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.74%.

RadNet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.93% to investors and pays a quarterly dividend of $0.75 per share. RadNet pays -- of its earnings as a dividend. Quest Diagnostics pays out 36.77% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

RadNet quarterly revenues are $461.1M, which are smaller than Quest Diagnostics quarterly revenues of $2.5B. RadNet's net income of $3.2M is lower than Quest Diagnostics's net income of $226M. Notably, RadNet's price-to-earnings ratio is 444.64x while Quest Diagnostics's PE ratio is 20.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RadNet is 2.94x versus 1.80x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

iSpecimen has a net margin of 0.7% compared to RadNet's net margin of -54.09%. RadNet's return on equity of -0.45% beat iSpecimen's return on equity of -118.86%.

RadNet has a consensus price target of $68.17, signalling upside risk potential of 23.91%. On the other hand iSpecimen has an analysts' consensus of -- which suggests that it could grow by 1900%. Given that iSpecimen has higher upside potential than RadNet, analysts believe iSpecimen is more attractive than RadNet.

RadNet has a beta of 1.768, which suggesting that the stock is 76.83% more volatile than S&P 500. In comparison iSpecimen has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RadNet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iSpecimen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RadNet pays -- of its earnings as a dividend. iSpecimen pays out -- of its earnings as a dividend.

RadNet quarterly revenues are $461.1M, which are larger than iSpecimen quarterly revenues of $2.7M. RadNet's net income of $3.2M is higher than iSpecimen's net income of -$1.4M. Notably, RadNet's price-to-earnings ratio is 444.64x while iSpecimen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RadNet is 2.94x versus 0.16x for iSpecimen. Usually stocks with elevated PS ratios are considered overvalued.

23andMe Holding has a net margin of 0.7% compared to RadNet's net margin of -134.11%. RadNet's return on equity of -0.45% beat 23andMe Holding's return on equity of -214.19%.

RadNet has a consensus price target of $68.17, signalling upside risk potential of 23.91%. On the other hand 23andMe Holding has an analysts' consensus of -- which suggests that it could grow by 156.27%. Given that 23andMe Holding has higher upside potential than RadNet, analysts believe 23andMe Holding is more attractive than RadNet.

RadNet has a beta of 1.768, which suggesting that the stock is 76.83% more volatile than S&P 500. In comparison 23andMe Holding has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RadNet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 23andMe Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RadNet pays -- of its earnings as a dividend. 23andMe Holding pays out -- of its earnings as a dividend.

RadNet quarterly revenues are $461.1M, which are larger than 23andMe Holding quarterly revenues of $44.1M. RadNet's net income of $3.2M is higher than 23andMe Holding's net income of -$59.1M. Notably, RadNet's price-to-earnings ratio is 444.64x while 23andMe Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RadNet is 2.94x versus 0.32x for 23andMe Holding. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of 0.7% compared to RadNet's net margin of 3.64%. RadNet's return on equity of -0.45% beat Progyny's return on equity of 11.31%.

RadNet has a consensus price target of $68.17, signalling upside risk potential of 23.91%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 31.5%. Given that Progyny has higher upside potential than RadNet, analysts believe Progyny is more attractive than RadNet.

RadNet has a beta of 1.768, which suggesting that the stock is 76.83% more volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

RadNet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RadNet pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

RadNet quarterly revenues are $461.1M, which are larger than Progyny quarterly revenues of $286.6M. RadNet's net income of $3.2M is lower than Progyny's net income of $10.4M. Notably, RadNet's price-to-earnings ratio is 444.64x while Progyny's PE ratio is 24.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RadNet is 2.94x versus 1.24x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.